KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Current Deferred Revenue (2018 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Current Deferred Revenue for 7 consecutive years, with $4.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Current Deferred Revenue rose 6.92% year-over-year to $4.6 million, compared with a TTM value of $4.6 million through Sep 2025, up 6.92%, and an annual FY2024 reading of $11.0 million, up 128.59% over the prior year.
  • Current Deferred Revenue was $4.6 million for Q3 2025 at Aurinia Pharmaceuticals, down from $5.5 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $11.0 million in Q4 2024 and bottomed at $190000.0 in Q4 2021.
  • Average Current Deferred Revenue over 5 years is $4.5 million, with a median of $4.6 million recorded in 2025.
  • The sharpest move saw Current Deferred Revenue skyrocketed 1556.84% in 2022, then decreased 7.68% in 2024.
  • Year by year, Current Deferred Revenue stood at $190000.0 in 2021, then surged by 1556.84% to $3.1 million in 2022, then surged by 52.89% to $4.8 million in 2023, then soared by 128.59% to $11.0 million in 2024, then crashed by 58.17% to $4.6 million in 2025.
  • Business Quant data shows Current Deferred Revenue for AUPH at $4.6 million in Q3 2025, $5.5 million in Q2 2025, and $4.6 million in Q1 2025.